Testing PreCursor-M+® for CIN2 management
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new tool called PreCursor-M+® to see how well it helps doctors manage CIN2, a moderate cervical cell change. It’s for people who have already been diagnosed with CIN2 and know their HPV test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with CIN2 (a moderate abnormal cell change in the cervix) after a biopsy or a treatment like a LEEP or laser conization.
- You know the results of your HPV test.
- You can understand and sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new method using low-temperature argon plasma to treat cervical precancer (CIN 2) and compares it with the standard approach of active surveillance. If you have CIN 2 and are between 18 and 40 years old, this trial may offer an alternative to watching and waiting.
This trial looks at proteins in cervical biopsy tissue to better understand how precancerous lesions develop and to predict their outcome. It may help find better ways to diagnose and monitor these changes in the future.
This study follows women with an early abnormal cervix cell change (CIN2/CIN2-3) to see how HPV DNA “integration” relates to whether the condition improves or worsens. It may help doctors better predict prognosis and guide safer monitoring, especially if you want to become pregnant.
This trial checks whether “therapy abstention” (not treating right away) and close monitoring is safe for certain high-grade cervical cell changes. It may help some people avoid immediate procedures while still catching any progression early.
This study tests a special light-based treatment (called HAL-PDT) for early cervical changes (CIN2) that were found on a recent biopsy. The goal is to see if this treatment can safely remove these changes and prevent them from becoming cancer.
This trial is testing a new screening tool (ELEVATE) to see how well it works in detecting cervical precancer. If you have an abnormal pap smear or a positive HPV test and are scheduled for a colposcopy, you may be able to help validate this tool.
Hear when a new Cervical Intraepithelial Neoplasia Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.